- Home
- BTE vs CADL Comparison
BTE vs CADL Comparison
Compare BTE & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTE | CADL |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BTE | CADL |
|---|---|---|
| Price | $3.13 | $5.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | ★ 18.2M | 1.0M |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,194,819,404.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $4.25 |
| 52 Week High | $3.32 | $13.68 |
Technical Indicators
Market Signals| Indicator | BTE | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 56.61 |
| Support Level | $3.03 | $5.48 |
| Resistance Level | $3.11 | $5.98 |
| Average True Range (ATR) | 0.11 | 0.43 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 44.33 | 53.12 |
Price Performance
Historical ComparisonAbout BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.